Clinical Trial Update: Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of ZL-2306 (niraparib) in platinum-sensitive relapsed ovarian cancer is ongoing, with current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-sensitive Relapsed Ovarian Cancer

Drugs mentioned

• ZL-2306 (niraparib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Platinum-sensitive Relapsed Ovarian Cancer | Phase 3 | Status: UNKNOWN